Pharmaceutical sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd. Clinical Trials
Studies where Shanghai Huaota Biopharmaceutical Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 11Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis
This trial is a 58 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of HB0056, either on top of stable IPF therapy or as monotherapy, are…
- Trial name
- NCT07909655
- Testing
- HB0056
- Where
- 2 sites in China
- Volunteers
- 75 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
First-line pMMR Endometrial Cancer
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer
This is a multicenter, randomized, double-blind, placebo controlled Phase III clinical trial, aiming to evaluate the efficacy and safety of HB0025 combined with chemotherapy (paclitaxel plus carboplatin) versus placebo combined…
- Trial name
- NCT07902999
- Testing
- HB0025 Injection, Paclitaxel injection, Carboplatin injection
- Where
- 2 sites in China
- Volunteers
- 333 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Asthma
A Study of HB0056 in Adult Participants With Moderate to Severe Asthma
The goal of this clinical trial is to learn if drug HB0056 works to treat severe asthma in adults. It will also learn about the safety of drugHB0056.
- Trial name
- NCT07899996
- Testing
- HB0056
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Acne Vulgaris
A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.
- Trial name
- NCT07449156
- Testing
- HB0043
- Where
- China
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Non Squamous Non-small Cell Lung Cancer
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer
This study is a randomized, controlled, double-blind, multicenter Phase III registration clinical trial, aiming to evaluate the efficacy and safety of HB0025 combined with chemotherapy (pemetrexed plus carboplatin/cisplatin)…
- Trial name
- NCT07383116
- Testing
- Pemetrexed injection, Carboplatin Injection, Cisplatin injection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Squamous Non-small Cell Lung Cancer
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
This study is a randomized, controlled, double-blind, multi-center phase III registration clinical trial, aiming to observe, compare and evaluate the efficacy and safety of HB0025 combined with paclitaxel + carboplatin compared…
- Trial name
- NCT07360132
- Testing
- Carboplatin Injection, Paclitaxel Injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Hidradenitis Suppurativa
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.
- Trial name
- HB0043-HS-0-01 (NCT06895499)
- Testing
- HB0043
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Solid Tumors
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors
- Trial name
- NCT06992687
- Testing
- HB0052 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Generalized Pustular Psoriasis (GPP)
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute…
- Trial name
- NCT06231381
- Testing
- HB0034
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Healthy
A Study to Evaluate HB0034 in Healthy Chinese Adult Participants
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose or multiple dose.
- Trial name
- NCT06716151
- Testing
- HB0034
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.